We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
President Trump on Wednesday signed into law the Right-to-Try Act establishing a pathway for terminally ill patients to use non-FDA-approved drugs, calling the legislation “great for the people” and a “fundamental freedom,” but it was a castoff remark he made about lower drug prices that had everyone talking. Read More
Veterans Health Administration officials are still not routinely checking records before writing opioid prescriptions, not regularly testing patients to make sure the drugs are being used properly and not properly securing informed consent before putting veterans on long-term opioid programs, according to the Government Accountability Office. Read More
More than three dozen state attorney’s general wrote Congress in support of bills that would increase penalties for opioid manufacturers that fail to report suspicious orders. Read More
Patients with tears in their digestive tracts should generally be excluded from clinical trials of drugs designed to treat complicated intra-abdominal infections, the FDA says. Read More
Despite opposition from some stakeholders, the European Commission proposes to grant waivers to Europe’s drugmakers to produce generic drugs for export to countries outside the EU. Read More
The announcement “likely signals that China is gearing up its enforcement efforts and looking into those industries that are most prone to corruption risk, particularly the pharmaceutical industry,” the attorneys said. Read More
An administrative law judge tossed out the Federal Trade Commission’s complaint challenging an agreement between Impax Laboratories and Endo Pharmaceuticals that the FTC claims illegally kept a generic version of the opioid pain medication Opana ER off the market. Read More